Showing 5701-5710 of 8473 results for "".
- Clear Clinic Acne Treatment Center Launches New Line, Online Componenthttps://practicaldermatology.com/news/20131119-clear_clinic_acne_treatment_center_launches_new_line_online_component/2459410/Clear Clinic Acne Treatment is launching a line of customized acne products along with an online program. Clear Clinic Online combines customized regimens from a new line of 19 acne products with guided care from a Personal Acne Coach, who will conduct consultations via video e-chat or telephone. Cl
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- Onset Dermatologics Acquires Worldwide Rights to Clindagel from Galderma Laboratorieshttps://practicaldermatology.com/news/20131031-onset_dermatologics_acquires_worldwide_rights_to_clindagel_from_galderma_laboratories/2459425/Onset Dermatologics, LLC recently announced the acquisition of Clindagel (clindamycin phosphate gel 1%), a prescription topical antibiotic for the treatment of acne, from Galderma Laboratories. Clindagel is the only FDA-approved topical form
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Pfizer Announces Top-Line Results of Two Phase III Clinical Trials Of Tofacitinibhttps://practicaldermatology.com/news/20131021-pfizer_announces_top-line_results_of_two_phase_iii_clinical_trials_of_tofacitinib/2459433/Pfizer, Inc. recently announced top-line results from two Phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chro
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- Hair Restoration Doctors Name Best Celebrity Hair, Meeting Convenes October 23https://practicaldermatology.com/news/20131010-hair_restoration_doctors_name_best_celebrity_hair_meeting_convenes_october_23/2459438/Singer/songwriter John Mayer and “Modern Family” star Sofia Vergara are the male and female celebrities with the most sought-after hair, according to results of the International Society of Hair Restoration Surgery (ISHRS) member survey released rec
- Valeant to Help Raise Awareness of Domestic Violencehttps://practicaldermatology.com/news/20131002-valeant_to_help_raise_awareness_of_domestic_violence/2459444/Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) is partnering with the National Coalition Against Domestic Violence (NCADV) to help raise awareness of domestic violence. As p
- TSLMS Announces New Name for its Meeting: Symposium for Cosmetic Advances and Laser Educationhttps://practicaldermatology.com/news/20131001-tslms_announces_new_name_for_its_meeting_symposium_for_cosmetic_advances_and_laser_education/2459447/The Tennessee Society for Laser Medicine & Surgery (TSLMS) announced that its 9th annual meeting Feb. 22-Mar. 2, 2014. The TSLMS introduced
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the